Drugs / DPX-Survivac(Aqueous)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03332576 | Aug 2013 → Sep 2016 | fallopian tube cancer, ovarian epithelial tumor, peritoneum cancer | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DPX-Survivac(Aqueous) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03332576 ↗ |
| Modality | Vaccine | “cancer vaccine” NCT03332576 ↗ |
| Route | Subcutaneous | “SubQ injection” NCT03332576 ↗ |